Sponsor Pipeline

Vir Biotechnology, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
8
Active Trials
4
Recruiting
2
Phase 3
1
Disease Areas
Active Trials by Phase
Phase 3
2
Phase 2
2
Phase 1/2
1
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06903338 A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Viral Hepatitis Active, Not Recruiting
NCT07128550 A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not… Viral Hepatitis Active, Not Recruiting
Phase 2
NCT07142811 A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Viral Hepatitis Active, Not Recruiting
NCT05461170 SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. Hepatitis D, Chronic Active, Not Recruiting
Phase 1/2
NCT05356741 To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in… Locally Advanced or Metastatic HER2-Expressing Cancers Recruiting
Phase 1
NCT05484206 Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Hepatic Impairment Recruiting
NCT06960395 Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants… Solid Tumor Malignancies Recruiting
NCT05997615 Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate… Hormone-refractory Prostate Cancer Recruiting
Disease Areas
Prostate Cancer (1)
Get alerts when Vir Biotechnology, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free